Safety of Recombinant Adeno-Associated Virus Type 2-RPE65 Vector Delivered by Ocular Subretinal Injection

Academic Article

Abstract

  • AAV2 delivery of the RPE65 gene to the retina of blind RPE65-deficient animals restores vision. This strategy is being considered for human trials in RPE65-associated Leber congenital amaurosis (LCA), but toxicity and dose efficacy have not been defined. We studied ocular delivery of AAV-2/2.RPE65 in RPE65-mutant dogs. There was no systemic toxicity. Ocular examinations showed mild or moderate inflammation that resolved over 3 months. Retinal histopathology indicated that traumatic lesions from the injection were common, but thinning within the injection region occurred only at the two highest vector doses. Biodistribution studies at 3 months postinjection showed no vector in optic nerve or visual centers in the brain and only isolated non-dose-related detection in other organs. We also performed biodistribution studies in normal rats at about 2 weeks and 2 months postinjection and vector was not widespread outside the injected eye. Dose-response results in RPE65-mutant dogs indicated that the highest 1.5-log unit range of vector doses proved efficacious. The efficacy and toxicity limits defined in this study lead to suggestions for the design of a subretinal AAV-2/2.RPE65 human trial of RPE65-associated LCA. © 2006 The American Society of Gene Therapy.
  • Authors

    Published In

  • Molecular Therapy  Journal
  • Digital Object Identifier (doi)

    Author List

  • Jacobson SG; Acland GM; Aguirre GD; Aleman TS; Schwartz SB; Cideciyan AV; Zeiss CJ; Komaromy AM; Kaushal S; Roman AJ
  • Start Page

  • 1074
  • End Page

  • 1084
  • Volume

  • 13
  • Issue

  • 6